RxDoctor Payments Data

Rifat Khan, MD

Interventional Pain Medicine · Oak Lawn, ILNPI 1972546877

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.0% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Edwards Lifesciences at 48.7% of the total. Reporting peaked in 2024 at $558 and has fallen 90.0% since, to $56 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in IL, where the typical reported total is $2,254.

$997in general payments, 2019–2025

Across 16 payments — averaging $62.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$486
  • BD$276
  • Merck$121
  • Takeda Pharmaceuticals U.S.A., Inc.$69
  • Pacira Pharmaceuticals Incorporated$24
  • Vyaire Medical, Inc.$22
$730,315in research payments, 2019–2025

Across 3 payments — averaging $243,438 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$730K

What the payments were for

  • Food & beverage$98799%
  • Education$101%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$997 in reported general payments places this provider in the 35th percentile of 93 interventional pain medicine providers in Illinois.

See all interventional pain medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$60,319
Medicare patients
294
Services billed
363

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other interventional pain medicine in Oak Lawn

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →